The two patients arrived in the intensive care unit under very different circumstances. The first was a 22-year-old man who suffered a pulseless electrical activity arrest following an intentional barbiturate overdose. The second was a 68-year-old man who developed ventricular fibrillation after acute respiratory distress and required 22 minutes of cardiopulmonary resuscitation before his circulation returned. Both received targeted temperature management, a protocol of controlled cooling and rewarming designed to protect the injured brain, and in the second patient, sedative medications were discontinued after 48 hours. In line with the 2023 Neurocritical Care Society guidelines and other international consensus recommendations, the clinical team deferred formal neuroprognostication until at least 72 hours after return of spontaneous circulation and the completion of rewarming. When that window arrived, both patients remained comatose and showed no motor response to pain — a finding that, on its own, already weighs heavily against a favorable outcome.

It was the electroencephalographic data, however, that painted the grimmer picture. Continuous EEG monitoring had been initiated within the first 24 hours after cardiac arrest in both patients. In the first patient, recordings obtained during the initial 72 hours showed a persistently suppressed, nonreactive background. In the second, the EEG initially demonstrated severe background suppression followed by generalized periodic discharges superimposed on a low-voltage, nonreactive background. Under current guidelines, both patterns fall into the category Westhall and colleagues originally labeled “highly malignant,” and both are treated as moderately reliable predictors of poor functional outcome when recorded at least 72 hours after return of spontaneous circulation, in the absence of sedation and other confounders. The apparent specificity of these patterns is precisely what gives them their clinical weight: in large cohort studies, patients exhibiting suppressed or burst-suppression backgrounds weeks of observation aside rarely, if ever, wake up.

But then came the twist. Brain magnetic resonance imaging, performed on day 4 for the first patient and day 3 for the second, told a strikingly different story. The first patient’s MRI was entirely unremarkable — no restricted diffusion, no cortical laminar necrosis, no evidence whatsoever of diffuse hypoxic-ischemic brain injury. The second patient’s scan showed only subtle bilateral abnormalities in the caudate nuclei, without any of the widespread cortical and deep gray matter changes that characterize catastrophic anoxic injury. According to the 2023 Neurocritical Care Society guidelines, a diffuse pattern of restricted diffusion involving both cortex and deep gray matter, obtained between 2 and 7 days after return of spontaneous circulation, is considered a moderately reliable predictor of poor outcome. The converse is also meaningful: the absence of diffusion-weighted abnormalities, or the presence of only isolated lesions, is generally associated with a greater likelihood of favorable recovery. In these two patients, the imaging did not definitively exclude hypoxic-ischemic injury, but it dramatically lowered the probability of irreversible, devastating brain damage — and that discordance between the EEG and the MRI created a genuine prognostic dilemma with immediate, life-and-death implications for decisions about withdrawing life-sustaining treatment.

The authors systematically dissect the reasons why an EEG pattern can be “falsely malignant.” Hypothermia, or incomplete rewarming, can suppress cortical activity and reproduce highly malignant features even when neuronal viability is preserved. Timing matters enormously: EEG findings are dynamic, time-dependent markers, and recordings obtained too early may not yet reflect the true extent of injury. Residual sedation, impaired drug clearance, or sedative stacking can markedly reduce EEG continuity and reactivity, mimicking suppression or burst-suppression patterns that vanish once pharmacological effects resolve — a mechanism directly illustrated by the first patient, in whom persistent barbiturate detection prompted continuous veno-venous hemofiltration to accelerate drug elimination. Metabolic derangements, too, can transiently depress cortical activity and generate malignant-appearing tracings. The lesson is that a highly malignant EEG is a conditional finding, valid only when the conditions under which it was recorded are known to be clean.

MRI interpretation demands equal caution. Even within the optimal imaging window, MRI may underestimate the extent of hypoxic-ischemic injury when damage is subtle, predominantly subcortical, or still evolving. Diffusion-weighted abnormalities may be absent early after arrest, and conversely may normalize if imaging is performed too late, reducing the sensitivity of diffusion sequences. Prognostic accuracy also depends on sequence selection, timing, and interpretive expertise. Although not routinely recommended, quantitative diffusion analysis and advanced techniques such as magnetic resonance spectroscopy may provide complementary information in selected cases. The critical principle, the authors emphasize, is that MRI findings must be interpreted within a dynamic, multimodal framework rather than in isolation — precisely because a single reassuring or alarming result can mislead if stripped of context.

The discordant prognostic picture extended well beyond imaging. The 2023 guidelines hold that bilateral absence of pupillary light responses at 72 hours or later after return of spontaneous circulation is a reliable predictor of poor outcome, whereas partial preservation of brainstem reflexes is less specific. In these patients, the reflexes told a nuanced story: the first had preserved pupillary reflexes despite absent corneal responses, and the second had sluggish pupillary reflexes with preserved corneal responses. Biomarkers added further reassurance. Neuron-specific enolase, measured within the first 72 hours after resuscitation, was low in the first patient at 7.6 nanograms per milliliter — far below the thresholds of roughly 60 to 80 nanograms per milliliter associated with poor outcome. Somatosensory evoked potentials in the second patient demonstrated preserved bilateral N20 responses; bilateral absence of the cortical N20 response at 48 hours or later is a reliable predictor of poor outcome, and its preservation, while not independently predictive of good recovery, is undeniably reassuring. Taken together, these findings reduced confidence in an invariably poor prognosis and supported continued life-sustaining treatment with serial reassessment.

What followed was a vindication of that patience. In the first patient, from day 5 onward the EEG showed progressive recovery of background continuity and reactivity. Approximately seven days after the arrest, he began to awaken, eventually returning to his premorbid neurological baseline. In the second patient, life-sustaining treatment was continued despite the malignant EEG. On day 7, an electroclinical seizure was documented, with diffuse myoclonus accompanied by central sharp waves; treatment with levetiracetam and valproic acid abolished the myoclonus and improved the electroencephalogram. Over the following days, the EEG showed recovering background organization and reactivity, with progressive reduction of the periodic discharges. The patient regained consciousness and was discharged to rehabilitation. Both patients, despite initially highly malignant EEG patterns, recovered from coma and achieved meaningful neurological recovery.

The authors distill several lessons for clinicians confronting similar scenarios. Highly malignant EEG patterns, although highly specific for unfavorable outcome in carefully controlled conditions, should never be interpreted in isolation; their significance can be distorted by timing, temperature, sedation, metabolic disturbances, and drug accumulation. A normal or only mildly abnormal brain MRI, together with preserved brainstem reflexes — particularly pupillary responses — and the presence of purposeful motor responses, should prompt caution against early pessimistic prognostication. All available indicators must be systematically integrated within a multimodal framework. Perhaps most strikingly, delayed recovery emerges as a clinically relevant phenotype: patients may follow protracted but meaningful recovery trajectories that current guideline timeframes do not fully capture.

For families and surrogates, the counseling implications are equally clear. When prognostic tests conflict, clinicians should explicitly acknowledge uncertainty and avoid anchoring decisions to any single modality. Families should understand that meaningful recovery may still occur when prognostic information is discordant, and that an extended period of observation may be warranted when it aligns with the patient’s values and goals of care. In an era when withdrawal of life-sustaining treatment decisions are often made within days of a cardiac arrest, these two recoveries stand as a sobering reminder that the brain’s capacity for resilience can exceed what its earliest signals suggest — and that in neuroprognostication, humility is not just a virtue but a clinical necessity.

The achievement is important because laboratory models often simplify cancer biology. Many commonly used cell lines have been maintained for years, sometimes decades, under artificial conditions. They can be extraordinarily useful for testing drugs and studying molecular pathways, but they may represent only one surviving branch of a tumor’s history. A single myeloma patient, by contrast, can harbor numerous related malignant populations with different mutations, gene-expression programs, growth rates and dependencies. By generating several cell lines from one disease course, the researchers created an experimental system in which those differences can be studied side by side rather than inferred from unrelated patients or isolated tissue samples.

Multiple myeloma begins in plasma cells, immune cells whose normal role is to produce antibodies in the bone marrow. During malignant transformation, plasma cells expand abnormally and often produce a detectable monoclonal immunoglobulin, while disrupting bone metabolism, blood-cell production and kidney function. The cancer is not static. Under pressure from the immune system, the bone-marrow environment and successive therapies, some subclones may be eliminated while others survive and expand. This process, known as branched clonal evolution, can lead to relapse and drug resistance. The new cell-line panel offers researchers a way to examine that process experimentally, including the possibility that cell populations collected from the same patient may behave differently despite sharing a common origin.

Establishing a cancer cell line is itself a demanding biological selection process. Cells must survive removal from the patient, adapt to culture conditions and continue dividing outside the protective and highly specialized bone-marrow niche. Plasma-cell malignancies can be particularly difficult to maintain because their growth depends on signals from surrounding stromal cells, cytokines, adhesion molecules and metabolic conditions. Cells that successfully become long-term cultures are therefore not necessarily a perfect census of the original tumor; they are populations capable of adapting to laboratory life. The significance of this study lies in producing multiple such cultures from one patient’s disease course and then characterizing them sufficiently to determine how closely they remain related and where they diverge.

Characterization typically involves combining several layers of evidence. Researchers can compare cell morphology, surface-marker profiles, immunoglobulin expression, chromosome structure, DNA sequence alterations and patterns of gene activity. These analyses help establish whether cultures are truly derived from the same patient, distinguish malignant plasma cells from contaminating populations and identify changes accumulated during disease progression or laboratory adaptation. Functional assays can then test proliferation, survival, drug sensitivity and interactions with relevant signaling pathways. Taken together, these measurements transform a cell line from a source of experimental material into a biological model with a documented identity and defined behavior.

The phrase “immortalizes clonal heterogeneity” captures the central value of the work. In a clinical sample, clonal diversity is often visible only at one moment, because a biopsy or blood specimen provides a snapshot of a moving evolutionary process. Once the cells are frozen, consumed in experiments or altered by treatment, that exact mixture may be impossible to reconstruct. Stable cell lines can preserve representative populations for repeated study, allowing scientists in different laboratories to revisit the same biological material. When several lines originate from different stages of one patient’s illness, investigators can ask whether relapse-associated populations display distinctive vulnerabilities, whether resistance emerges through new mutations or pre-existing minor clones and which molecular features remain constant across the disease.

This approach may also sharpen the interpretation of drug-response experiments. A treatment that appears highly effective in one myeloma cell line may fail against another because the cells rely on different survival circuits. Some populations may depend more strongly on proteasome function, DNA-damage repair, anti-apoptotic proteins or signals from the bone-marrow microenvironment. Others may enter slow-cycling states that make them less sensitive to drugs targeting rapidly dividing cells. Testing therapies across a matched panel of cell lines from one patient could therefore reveal both shared vulnerabilities and clonal escape routes. Such results would not automatically predict what will happen in a patient, but they could expose mechanisms that are hidden when experiments rely on a single model.

The resource is also relevant to precision oncology, where the goal is to match treatment to the molecular features of an individual cancer. Precision medicine is often discussed as if a tumor has one defining genetic signature, but multiple myeloma illustrates why that assumption can be incomplete. Different subclones may carry overlapping yet nonidentical alterations, and the dominant population in a diagnostic sample may not be the one that drives relapse. A panel representing several points in the same disease trajectory provides a framework for testing whether a proposed target is broadly shared or restricted to one branch of the tumor. It may also help researchers design combinations intended to prevent resistant populations from taking over.

At the same time, the investigators’ model must be interpreted with appropriate caution. Long-term culture can change cancer cells, favoring populations that grow efficiently in plastic dishes rather than in human bone marrow. Cell lines lack the full architecture of the patient’s body, including immune cells, stromal networks, blood-vessel signals and fluctuating drug concentrations. They may therefore preserve important features of clonal biology while losing others. The strongest applications will likely combine these lines with primary patient samples, three-dimensional cultures, organoid-like systems and animal models. Their greatest contribution may be as a controlled bridge between complex clinical material and mechanistic laboratory experiments.

By converting one patient’s changing myeloma into a set of renewable, comparable models, the Blood Cancer Journal study addresses a fundamental weakness in cancer research: the tendency to treat a heterogeneous disease as a single entity. The resulting cell lines cannot reproduce every dimension of the original illness, but they can make evolution, divergence and treatment response experimentally visible. For scientists investigating why multiple myeloma returns, how resistant clones emerge and which therapies can eliminate more than one malignant population, that visibility is powerful. The work offers a durable platform for studying cancer as an evolving ecosystem rather than a fixed target—and a reminder that the most informative laboratory model may sometimes be built not from many patients, but from the changing biology of one.

Subject of Research: Multiple myeloma clonal heterogeneity and the establishment and characterization of cell lines from different stages of a single patient’s disease course

Article Title: Establishment and characterization of multiple myeloma cell lines from a single patient’s disease course immortalizes clonal heterogeneity

Article References: Wiedmeier-Nutor, J., Riggs, D., Stein, C. et al. “Establishment and characterization of multiple myeloma cell lines from a single patient’s disease course immortalizes clonal heterogeneity.” Blood Cancer Journal (2026). https://doi.org/10.1038/s41408-026-01597-6

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41408-026-01597-6

Keywords: Multiple myeloma, clonal heterogeneity, cancer cell lines, clonal evolution, plasma cells, drug resistance, precision oncology, disease progression

The research, led by Zhang, Tuffen and Wadsworth and published in Nature Communications, focuses on sustained ash emission during lava effusion at silicic volcanoes. Silicic magma contains high levels of silica, making it viscous and resistant to flow. Unlike fluid basaltic lava, which can travel relatively easily, silicic lava often forms domes, spines or short, thick flows near a vent. These eruptions are commonly perceived as less explosive because magma is visibly moving rather than violently fragmenting. The study challenges that assumption, showing that effusive activity can still generate persistent ash emissions with significant consequences.

Ash is produced when magma or solidified volcanic rock breaks into fragments smaller than two millimetres. In explosive eruptions, this fragmentation is usually driven by expanding gas bubbles trapped inside rapidly rising magma. During lava effusion, however, ash can be generated through a more gradual process. As viscous magma is pushed toward the surface, it may develop a brittle outer crust while hotter material continues to rise beneath it. The interaction between these contrasting layers can cause the lava surface, dome margins or recently solidified rock to fracture and disintegrate.

The key physical problem is the unusual behavior of silicic lava. Its high viscosity prevents gases from escaping easily, while cooling rapidly increases its resistance to deformation. This can produce a material that behaves like a fluid deep inside the conduit but like a brittle solid closer to the surface. When the pressure, shear stress or internal gas content becomes sufficiently high, the rigid material may crack and be pulverized. Instead of producing one short-lived explosion, the process can continue as long as fresh magma supplies heat, gas and mechanical stress to the erupting structure.

That distinction matters because sustained ash emission may look modest when compared with a major explosive eruption. The ash plume can be lower, thinner or partially obscured by weather, while the lava itself remains the most visible feature. Yet a prolonged release may contaminate air over a wide area, reduce visibility, irritate the respiratory system and damage machinery. Fine ash particles can enter aircraft engines, interfere with electrical infrastructure and spread far beyond the immediate lava front, particularly when winds transport them through populated regions.

The study also highlights why conventional visual assessments may fail to identify the danger quickly. Observers may interpret the absence of a large eruption column as evidence that the volcano is relatively stable. But ash production can occur through fragmentation at the lava surface or within a growing dome, processes that do not necessarily generate the intense seismic or atmospheric signals associated with explosive eruptions. Monitoring teams therefore need to treat changes in ash output, plume persistence, lava texture and dome deformation as potentially connected signals rather than isolated observations.

For volcanologists, the findings offer a more detailed picture of how magma turns into ash during effusion. The process may involve repeated cycles of pressurization, cracking, collapse and renewal. Gas-rich pockets can expand as magma ascends, weakening the lava from within. At the same time, the outer surface cools and becomes brittle. Friction and deformation then concentrate along narrow zones, where the lava can fragment into fine particles. Each small failure may expose fresh magma to the atmosphere, allowing the cycle to continue and creating a sustained ash source without a single catastrophic trigger.

The discovery has direct implications for hazard forecasting. Emergency plans often divide eruptions into broad categories, treating explosive activity as an immediate high-risk phase and effusive activity as comparatively manageable. The new research indicates that this binary approach is too simple for silicic systems. A volcano can be effusive in terms of lava movement while behaving explosively at a smaller scale through continuous fragmentation. Authorities may need to establish ash-related alerts even when lava extrusion remains steady and no large explosion has occurred.

The message is especially important because silicic volcanoes are capable of changing behavior rapidly. A period of apparent calm or slow lava growth can conceal increasing gas pressure, structural instability or the formation of brittle zones within a dome. Sustained ash emission may therefore serve not only as a hazard in its own right but also as a warning that the eruptive system is mechanically and thermally active. By combining geological observations with gas measurements, seismic data, satellite imagery and real-time ash detection, scientists may be able to recognize these transitions earlier.

The study reframes lava effusion as a process that can be both quiet and dangerous. The absence of a spectacular explosion does not mean that a silicic eruption is harmless, particularly when ash is being produced continuously. As monitoring networks expand and researchers develop better models of magma fragmentation, this hidden form of volcanic activity is likely to become a central concern in eruption response. The volcano may appear to be simply building a lava dome, but above and around it, an invisible stream of microscopic rock can already be affecting the atmosphere, infrastructure and public health.

Subject of Research: Sustained ash emission during lava effusion in silicic volcanic eruptions

Article Title: Sustained ash emission during lava effusion is a hidden volcanic hazard of silicic eruptions

Article References: Zhang, J., Tuffen, H., Wadsworth, F.B. et al. “Sustained ash emission during lava effusion is a hidden volcanic hazard of silicic eruptions.” Nature Communications (2026). https://doi.org/10.1038/s41467-026-76464-w

Image Credits: AI Generated

DOI: 10.1038/s41467-026-76464-w

Keywords: volcanic ash, silicic eruptions, lava effusion, magma fragmentation, volcanic hazards, ash emissions, lava domes, eruption monitoring

Multiple myeloma is characterized by the malignant proliferation of plasma cells, which are responsible for producing antibodies essential for immune defense. Approximately 20% of patients diagnosed with this condition exhibit a chromosomal abnormality, specifically a translocation between chromosomes 4 and 14 (t(4;14)). This results in the overexpression of the NSD2 gene, which is crucial for understanding MM pathogenesis. The research focuses on comparing two distinct types of myeloma cells: one exhibiting high levels of NSD2 activity and another where this gene’s expression is inhibited.

The researchers found that the activation of NSD2 leads to notable biochemical changes within the cells. Through a process known as epigenomic reprogramming, NSD2 alters the structural conformation of DNA, impacting the gene expression profiles within the cells. This modification is pivotal as it governs how certain genes, especially those associated with plasma cell differentiation and functionality, are regulated. When NSD2 is active, the cells display traits typical of mature plasma cells, essential for effective immune responses. However, silencing this gene prompts the reactivation of previously dormant genes, indicating a regression in their plasma cell characteristics.

Significantly, the study describes how differential expression of key cell surface markers, like CD38, which is commonly associated with plasma cell identity, becomes altered when NSD2 functionality is compromised. The reduction in CD38 levels demonstrated by the NSD2-deficient cells suggests a loss of plasma cell identity, raising questions about the implications for treatment strategies. The research posits that targeting NSD2 could influence the responsiveness of myeloma cells to existing therapies that rely on CD38 as a target.

Furthermore, the physical morphology and functional assays performed by the research team revealed that cells with active NSD2 exhibit features that correspond more closely to fully differentiated plasma cells. In stark contrast, those lacking NSD2 appeared less mature and adopted characteristics indicative of immature or earlier-stage cells. This underscores the critical role NSD2 plays not merely in maintaining identity but also in the survival and proliferation of these cancerous cells.

The implications of this research extend beyond basic understanding. As novel pharmacological agents that specifically inhibit NSD2 are being developed, the findings suggest that their application could fundamentally alter treatment modalities for patients with t(4;14) myeloma. The modulation of NSD2 activity could lead to a cascade of effects on downstream genes resulting in changes in drug efficacy and cellular behavior.

This research also emphasizes the complexity of tumor biology, where a single gene can orchestrate vast networks of gene expression and cellular functions. Understanding the multifaceted role of NSD2 offers a platform for the development of more refined treatment approaches. This could be particularly beneficial for patients who do not respond to conventional therapies that target larger, more visible pathways but instead require a nuanced strategy that takes into account the subtleties of their cancer’s genetic profile.

As the field continues to evolve, the investigation into NSD2 and its effects on multiple myeloma presents an excellent opportunity to explore how targeted therapies can be developed. The aim would be not only to inhibit tumor growth but also to maintain or restore the identity and function of plasma cells, a delicate balance essential for healthy immune responses.

The insights gleaned from the study indicate a clear need for continuous research into the molecular underpinnings of cancer. By leveraging advances in genomic and epigenomic analyses, researchers can better delineate the pathways that contribute to malignancy and treatment resistance. This advancement opens the door for potentially transformative approaches in clinical settings, ultimately hoping to reduce the burden of multiple myeloma.

In summary, this research reinforces the vital role of NSD2 in maintaining plasma cell identity while elucidating the complexities of cancer biology. It provides a clearer picture of how targeting specific molecular pathways can revolutionize treatment protocols for high-risk myeloma patients and possibly transform standards of care globally. This study not only underscores the importance of NSD2 as a therapeutic target but also highlights the need for ongoing exploration of the genetic landscape in cancer therapeutics.

By fostering greater understanding of genetic factors in multiple myeloma, this research continues the critical dialogue between basic science and clinical application. The aspiration is clear: to harness scientific discoveries in ways that yield tangible benefits for patients struggling with this challenging and often aggressive form of cancer.

Subject of Research: Cells
Article Title: NSD2-epigenomic reprogramming and maintenance of plasma cell phenotype in t(4;14) myeloma
News Publication Date: 21-Mar-2025
Web References: https://www.oncotarget.com/
References: 10.18632/oncotarget.28706
Image Credits: Copyright © 2025 Gunnell et al.
Keywords: cancer, myeloma, NSD2, t(4;14), CD38, plasma cell